Genesystem Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Operating Revenue	1,208	897.03	3,653
Other Revenue	0	0	-
Revenue	1,208	897.03	3,653
Revenue Growth (YoY)	34.64%	-75.44%	-
Cost of Revenue	3,028	2,483	2,486
Gross Profit	-1,820	-1,586	1,167
Selling, General & Admin	3,885	4,119	3,855
Research & Development	3,344	3,425	3,354
Other Operating Expenses	85.56	76.6	72.81
Operating Expenses	8,296	7,898	7,772
Operating Income	-10,116	-9,484	-6,605
Interest Expense	-136.25	-133.61	-95.47
Interest & Investment Income	300.54	363.75	205.31
Earnings From Equity Investments	-	882.76	-
Currency Exchange Gain (Loss)	70.28	76.04	234.36
Other Non Operating Income (Expenses)	7.12	124.59	29.27
EBT Excluding Unusual Items	-9,874	-8,171	-6,231
Gain (Loss) on Sale of Investments	194.97	258.36	-825.27
Gain (Loss) on Sale of Assets	-0.18	-	-3.14
Pretax Income	-9,679	-7,913	-7,060
Income Tax Expense	-150.73	146.41	1,936
Earnings From Continuing Operations	-9,529	-8,059	-8,996
Minority Interest in Earnings	613.41	143.55	-
Net Income	-8,915	-7,915	-8,996
Net Income to Common	-8,915	-7,915	-8,996
Shares Outstanding (Basic)	7	7	7
Shares Outstanding (Diluted)	7	7	7
Shares Change (YoY)	-1.47%	0.66%	-
EPS (Basic)	-1302.00	-1139.00	-1303.00
EPS (Diluted)	-1302.00	-1139.00	-1303.00
Free Cash Flow	-7,595	-8,174	-6,655
Free Cash Flow Per Share	-1109.26	-1176.26	-963.95
Gross Margin	-150.69%	-176.81%	31.96%
Operating Margin	-837.58%	-1057.33%	-180.80%
Profit Margin	-738.17%	-882.41%	-246.26%
Free Cash Flow Margin	-628.89%	-911.27%	-182.18%
EBITDA	-8,873	-8,939	-6,219
EBITDA Margin	-	-	-170.23%
D&A For EBITDA	1,242	545.39	386.3
EBIT	-10,116	-9,484	-6,605
EBIT Margin	-	-	-180.80%
Advertising Expenses	182.95	281.68	239.36

Updated Nov 14, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.